@Anand_88_Patel Caveat also these trials address transfusion dependent anemia. For symptomatic, but non transfused anemia, e.g. older LE-MDS patient with Hg hovering in the 9 range, many are treated, and think ESA still appropriate
We are proud of staff like Darryl Taylor, who works at Froedtert Hospital in Environmental Services. Darryl went the extra mile in his workday, offering support and friendship to patient Lindsey Jacob and her family. https://t.co/k2bh2yTLxb
@ReshmaRamlal2@Dr_AmerZeidan@MediHumdani@LRunaas Iomab delivers myeloablative ablative radiation - more “intense” than FLAMSA or FLAG-Ida + NMA/RIC. These results are in line with historical outcomes doing ablative transplants in PIF - 10-15% durable CR. Most don’t transplant these pts, but nothing better exists too…
@Dr_AmerZeidan If HCT improves OS, but doesn’t cure, would you not recommend HCT? That’s likely the case for TP53mut, monsomal/complex karyotype myeloid malignancies… it’s a concept I struggle with, I tend to say yes but it’s a valid question
We at @MedicalCollege are looking for energetic faculty looking to build a career in HCT & CART therapy with a focus on myeloid &/or plasma cell disorder. Home of @CIBMTR / @BMTCTN +
- No🌪️
- No
- No 🔥
- No 🌀
Chilly yes but warm Friendly people. DM or meet at Tandem #bmtsm
@Dr_AmerZeidan@CanerSaygin Recent ASH presentation presented on pts who went to HCT with disease on D14 marrow. Some of those patients are probably in remission, or have chemo sensitive disease. Not the same as “active disease” in a traditional sense
@MDPhD10@CLachowiez@TalhaBadarMD Ratify enrolled when AML was 20%. I don’t know if this patient, esp with MLD is someone you can extrapolate from Ratify experience. RAEB-2 always at this age would get recommended HCT.
Now, getting a little out there, some say that Ven is targeted therapy for NPM1, Ven-CLIA?
@sghmd@OpenAI I noticed that too! It cited a paper with exactly the data I was looking for to make a point, only to find after numerous searches that that paper doesn’t exist :(